Betaxolol Market - RegionalAnalysis
Geographically, global BetaxololMarket is segmented into North America, Latin America, Europe, AsiaPacific, Middle East, and Africa. North America holds the maximum share forocular surgery, owing to high prevalence of diabetes and eye related disordersamong the populace in the region. According to National Federation of theblind, 2014, around 1.3 million people were legally blind in the U.S. andestimated that over 75,000 people in the U.S. are expected to suffer fromblindness or visual impairment annually. Furthermore, Asia Pacific betaxololmarket is expected to witness significant growth owing to the presence ofgeneric key players such as Lupin Ltd. And Cipla Ltd. especially in India,which are engaged in manufacturing the generics of betaxolol to retain themarket share in the region.
Betaxolol is a racemic mixtureand beta-adrenergic receptor inhibitor used to treat patients with chronicopen-angle glaucoma or ocular hypertension. It was first approved by the U.S.Food and Drug Administration (FDA) in 1989, as an oral tablet. Betaxolol isused either alone or in combination with other medicines to lower down thepressure within the heart or eye. In the heart, Betaxolol decreases the cardiaccontractility and rate selectively by actively binding and blocking beta-1adrenergic receptors. This leads to reduction in cardiac output and lowersblood pressure. Topical applications in the eye reduces aqueous humor secretionand lowers the Intraocular Pressure (IOP) resulting in low risk of optic nervedamage and loss of vision in patients. Betaxolol further inhibits the releaseof renin, a hormone secreted by the kidneys that causes constriction of bloodvessels. However, lightheadedness, drowsiness, dizziness, and headache are someof the symptoms reported while taking this medication at initial stage. Fororal administration, Betaxolol is available as 10-mg and 20-mg tablets whereasin liquid form, it comes in 2.5, 5, 10, and 15 mL of bottles of 0.25% sterileophthalmic suspension and prescribed as one to two drops in the affected eyetwice daily.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1781
Betaxolol Market Drivers
Increasing prevalence of glaucomaworldwide is propelling growth of the market. According to the Glaucomaresearch Foundation, glaucoma is the leading cause of irreversible blindnessworldwide. Around 10% of the glaucoma patients who receive proper treatmentstill experience a loss of vision. Around 64.3 million people were estimated tobe suffering from glaucoma worldwide, in 2013. Furthermore, according to theAmerican Academy of Ophthalmology, the prevalence of glaucoma is high in Africaand Latin America. Patients who fail to respond to medications, undergotrabeculectomy surgery. However, few patients do not get complete relief fromglaucoma even after trabeculectomy surgery. Therefore, novel treatment optionsare required for providing relief to such patients. Reducing intra-ocularpressure is the most important long term medical need of refractory glaucomapatients, which can be overcome by the use of Betaxolol drug, this in turn is expectedto create lucrative opportunities for market growth. Moreover, people sufferingfrom diabetic retinopathy are more prone to glaucoma. The condition isassociated with abnormal blood vessel growth, which can result in retinopathyand leads to blockage of natural drainage of the eye. Thus, increase diabeticpatient pool may also augment the growth of the betaxolol market size.
Increasing prevalence ofhypertension diseases is also expected to drive growth of the market atsignificant rate. According to the reports from a variety of sources, includingCenters for Disease Control and Prevention (CDC) and World Health Organization(WHO) in 2015, the global prevalence of pulmonary arterial hypertension isprojected to be 100,000 – 200,000, that is about 15 - 50 patients per millionof the population. Although treatment available for pulmonary arterialhypertension is limited, beta-adrenergic receptor inhibitor, Prostacyclin andprostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors are available to decreasesymptoms, slow down disease progression, and improve the quality of life.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/betaxolol-market-1781
Betaxolol Market Restraint
Stringent regulatory approvals toensure the safety of drugs and patent expiry of betaxolol drugs such asBetoptic S and Betoptic Liq, are major challenge for growth of the market, asthe generic versions of these drugs are sold at 70% to 80% lower prices ascompared to the branded drugs.
Betaxolol Market – Competitive Landscape
Organic and inorganic strategiesby market players such as merger, collaboration, acquisition, and research anddevelopment for expansion of their business across the regions is expected toboost growth of the market. For instance, in 2016, Humanwell Healthcare Groupand PuraCap Pharmaceutical acquired Epic Pharma LLC for $550 million to expandboth their commercial and manufacturing capabilities, as well as their presencein the U.S. and international generics market.
The market players operating inbetaxolol market include Novartis AG, Genix Pharma (Pvt.) Ltd., East WestPharma, Hetero Healthcare Ltd. (GenX), Cadila Pharmaceuticals Ltd., JawaPharmaceuticals (INDIA) Pvt. Ltd., DAL Medical Services Company Ltd, SentissPharma Pvt. Ltd., Humanwell Healthcare Group, and PuraCap Pharmaceutical LLC.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1781
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
